Search
Sotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigational[L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed … 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m<sup>2</sup>.
Prezatide copper
go.drugbank.com/drugs/DB14683InvestigationalPrezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions [A19503]. Prezatide is used in cosmetic products for the skin and hair. … It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated.
DPI-221
go.drugbank.com/drugs/DB06121ExperimentalDPI-221 is an investigational drug and a selective agonist for the δ-opioid receptor.
Alanosine
go.drugbank.com/drugs/DB05540InvestigationalAn amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities.
Categories: Compounds used in a research, industrial, or household settingVarespladib methyl
go.drugbank.com/drugs/DB05737InvestigationalVarespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.
Categories: Phospholipase A2 InhibitorsRanpirnase
go.drugbank.com/drugs/DB04950InvestigationalRanpirnase is a ribonuclease enzyme found in <i>Rana pipiens</i> oocytes. It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. … It is the first ribonuclease to enter cancer clinical trials.
SYNB1020
go.drugbank.com/drugs/DB17667Investigationaldiscontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc.
PYM50018
go.drugbank.com/drugs/DB05126ExperimentalPYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). … When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time.
Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen
go.drugbank.com/drugs/DB10284ApprovedInvestigationalA and one from subfamily B (A05 and B01, respectively). … It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily
SYN-101
go.drugbank.com/drugs/DB05958ExperimentalSYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells. … SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer.